Molecular Response Breaking News Candel Therapeutics to Raise $80M in Public Stock and Warrants Offering Editas Medicine Lays off 65 Percent of Workforce; Drops Sickle Cell, TDT Candidate Reni-Cel Boundless Bio Ends Trial of BBI-825 in Patients With Certain Cancer Resistance Mutations In Brief This Week: Lantern Pharma, AstraZeneca, Genesupport, UniQure, PanGIA Biotech Leapfrog Bio to Begin Phase II Trial of Synthetic Lethal Candidate in Solid Tumors Natera Enrolls First Patients in Phase III SAGITTARIUS Colon Cancer Trial